U.S. National Institutes of Health
Last Updated: 09/05/08

About the Acting Branch Chief

Meg Mooney, MD

Meg Mooney, MD is currently Head of Gastrointestinal and Neuroendocrine Cancer Therapeutics in the Clinical Investigations Branch of the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, at the NCI. She was formerly the Interim Director of the Office of Evidence-Based Surgery at the American College of Surgeons in Chicago, Illinois.More…

Clinical Investigations Branch (CIB)

The Clinical Investigations Branch (CIB) is responsible for

  • Scientific coordination and oversight of the NCI's Clinical Trials Cooperative Group Program and of the adult and pediatric brain tumor consortia

  • Organization of comprehensive programs of preliminary and definitive clinical trials of innovative treatment, single/multiple agent or combined modalities, for adult, adolescent and pediatric populations

  • Facilitation and organization of clinical research including surgical and radiation therapy, as well as chemo-, biologic and immunotherapy in the treatment of cancer

  • Collaboration with other NCI programs and the extramural scientific community on disease-related and survivorship issues and their impact on oncology treatment trials

  • Coordination with other NCI programs regarding collection, banking, and use of clinical biospecimens in conjunction with validated data from clinical trials

  • Collaboration with Clinical Trials Cooperative Groups, consortia, cancer centers and other entities in the development/harmonization of research standards and methodologies

  • Collaboration with international clinical trials organizations and coordination of international planning and implementation for phase 3 oncology treatment trials

  • Facilitation of central institution review board for adult and pediatric cooperative group phase 3 oncology treatment trials

  • Oversight of pediatric drug development, from testing of novel agents through the Pediatric Preclinical Testing Program to clinical evaluations of novel agents by CIB-supported pediatric clinical trials organizations